Recruiting

Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System

The CHARGE-APP project will investigate whether an innovative management strategy of hypertension based on the combination of usual care visits and ESH CARE App compared to standard care, is associated with differences in outcome, including control rate of office, home and ambulatory BP, cardiovascular and renal intermediate end points at one year, and changes in a number of blood pressure-related variables throughout the study.

ClinicalTrials.gov IDNCT03206814

PhaseNA

Enrollment480

SponsorIstituto Auxologico Italiano

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Hypertension,Essential, Hypertension, Uncontrolled

About this study

Interventions

Other: Usual care — Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.
Other: POST-strategy — Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.

Primary outcomes

Ambulatory Systolic Blood Pressure (12 months)

Eligibility information

Inclusion Criteria: * Male and female subjects; * Age 18-80 years; * Either the patient or another person close to him/her should possess a smartphone compatible with the ESH CARE app and be capable of using it; * Uncontrolled (untreated or treated) hypertension, defined as office BP ≥140/90 mmHg, and Ambulatory 24h ABP ≥130/80 mmHg Exclusion Criteria: * eGFR \<45 mL/min/1.73 m2 (CKD-EPI creatinine equation 2009); * Severe uncontrolled hypertension (i.e. BP ≥200/120 mmHg despite treatment); * Known secondary hypertension; * Orthostatic hypotension (SBP fall \> 20 mmHg on standing); * Unstable clinical conditions or severe disease with short life expectation; * Known atrial fibrillation; * Hepatic disease as determined by either AST or ALT values \> 2 times the upper limit of normal; * History of gastrointestinal surgery or disorders which could interfere with drug absorption * History of malignancy including leukaemia and lymphoma (but not basal cell skin cancer) within the last 5 years; * History of clinically significant autoimmune disorders such as systemic lupus erythematosus; * History of drug or alcohol abuse within the last 5 years; * History of non-compliance to medical regimens and/or patients who are considered potentially unreliable; * Dementia (clinical diagnosis); * Inability or unwillingness to give free informed consent; * Inability to use even simple communication technologies; * Pregnancy or planned pregnancy during study period

Study locations

Private Hospital " Dr Raúl Matera", Bahía Blanca, B8000 Argentina
Argerich Hospital, Buenos Aires, C155 AHD Argentina
General San Martin Hospital of La Plata, La Plata, 1900 Argentina
Spanish Hospital of Mendoza, Mendoza, M5501 Argentina
British Sanatorium of Rosario, Rosario, S2000 Argentina
Shanghai Institute of Hypertension, Shanghai, Huangpu China
Jiangsu Province Official Hospital, Jiangse, 210024 China
Ruijin Hospital North, Shanghai, 200025 China

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.